AU3582593A - Antigen recognized by patients with antibody associated lambert-eaton myasthenic syndrome (LEMS), DNA encoding same and uses thereof - Google Patents

Antigen recognized by patients with antibody associated lambert-eaton myasthenic syndrome (LEMS), DNA encoding same and uses thereof

Info

Publication number
AU3582593A
AU3582593A AU35825/93A AU3582593A AU3582593A AU 3582593 A AU3582593 A AU 3582593A AU 35825/93 A AU35825/93 A AU 35825/93A AU 3582593 A AU3582593 A AU 3582593A AU 3582593 A AU3582593 A AU 3582593A
Authority
AU
Australia
Prior art keywords
lems
lambert
patients
dna encoding
antigen recognized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU35825/93A
Inventor
Henry M Furneaux
Jerome B Posner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sloan Kettering Institute for Cancer Research
Original Assignee
Sloan Kettering Institute for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Institute for Cancer Research filed Critical Sloan Kettering Institute for Cancer Research
Publication of AU3582593A publication Critical patent/AU3582593A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AU35825/93A 1992-01-10 1993-01-11 Antigen recognized by patients with antibody associated lambert-eaton myasthenic syndrome (LEMS), DNA encoding same and uses thereof Abandoned AU3582593A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82031292A 1992-01-10 1992-01-10
US820312 1992-01-10

Publications (1)

Publication Number Publication Date
AU3582593A true AU3582593A (en) 1993-08-03

Family

ID=25230462

Family Applications (1)

Application Number Title Priority Date Filing Date
AU35825/93A Abandoned AU3582593A (en) 1992-01-10 1993-01-11 Antigen recognized by patients with antibody associated lambert-eaton myasthenic syndrome (LEMS), DNA encoding same and uses thereof

Country Status (2)

Country Link
AU (1) AU3582593A (en)
WO (1) WO1993014098A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653097B1 (en) * 1991-08-15 2003-11-25 Merck & Co., Inc. Human calcium channel compositions and methods
CA1341170C (en) * 1988-04-04 2001-01-16 Steven B. Ellis Calcium channel compositions and methods
US6096514A (en) * 1988-04-04 2000-08-01 Sibia Neurosciences, Inc. Human calcium channel compositions and methods
US5874236A (en) * 1988-04-04 1999-02-23 Sibia Neurosciences. Inc. DNA encoding human calcium channel α-1A, β1, β-2, and β-4 subunits, and assays using cells that express the subunits
US5407820A (en) * 1988-04-04 1995-04-18 The Salk Institute Biotechnology/Industrial Associates, Inc. Calcium channel α-2 subunit DNAs and cells expressing them
US5386025A (en) * 1990-02-20 1995-01-31 The Salk Institute Biotechnology/Industrial Associates Calcium channel compositions and methods
US6387696B1 (en) * 1988-04-04 2002-05-14 Merck & Co., Inc. Human calcium channel compositions and methods
US6518397B1 (en) 1997-07-24 2003-02-11 Shoukat Dedhar Pharmaceuticals for modulating hormone responsiveness
WO1999005172A2 (en) * 1995-01-24 1999-02-04 Shoukat Dedhar Pharmaceuticals for modulating hormone responsiveness
US6528630B1 (en) 1997-12-03 2003-03-04 Merck & Co., Inc. Calcium channel compositions and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341170C (en) * 1988-04-04 2001-01-16 Steven B. Ellis Calcium channel compositions and methods
US5386025A (en) * 1990-02-20 1995-01-31 The Salk Institute Biotechnology/Industrial Associates Calcium channel compositions and methods

Also Published As

Publication number Publication date
WO1993014098A1 (en) 1993-07-22

Similar Documents

Publication Publication Date Title
AU1235392A (en) Cytokine-induced protein, tsg-14, dna coding therefor and uses thereof
EP0652436A3 (en) Bio-sensor for measuring alcohol concentration, method for manufacturing the bio-sensor and drunkometer using the same.
EP0962467A4 (en) Antibody against human parathormone related peptides
NL300249I1 (en) Cephalosporins and homologues, preparations and pharmaceutical preparations.
GB2185266B (en) Monoclonal antibodies cross-reactive and cross-protective against p. aeruginosa serotypes
AU7198291A (en) Human monoclonal antibodies against rabies viruses, the production and the use thereof
AU7949394A (en) Reconstituted human antibody against human medulloblastomatous cell
EP0608546A3 (en) Glia activating factor (gaf), antibodies against it and their uses.
AU3582593A (en) Antigen recognized by patients with antibody associated lambert-eaton myasthenic syndrome (LEMS), DNA encoding same and uses thereof
FR2706484B1 (en) Protein kinase C mutant polypeptide, nucleic acid sequences encoding said polypeptide, and uses thereof.
AU2712192A (en) Monoclonal antibodies against mycoplasma pneumoniae, hybridomas producing these, methods for the preparation thereof, and the use thereof
AU6775894A (en) Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
EP0669396A4 (en) Novel polypeptide and dna coding for the same.
AU1301797A (en) Polypeptides with interleukin 16 activity, process for the preparation and use thereof
AU5873994A (en) Immune response modulator complex, and uses thereof
AU2820992A (en) Polypeptide, dna fragment encoding the same, drug composition containing the same and process for producing the same
AU1534492A (en) Antigen recognized by patients with antibody associated paraneoplastic sensory neuronopathy, dna encoding same and uses thereof
EP0545547A3 (en) Immobilized enzyme film, protein immobilized film and process for forming the same
AU1440695A (en) P53-based polypeptide fragments, nucleic acid molecules encoding same, and uses thereof
AU4400293A (en) Methods for obtaining and purifying cell-free pneumococcal surface proteins from (s. pneumoniae) and use thereof
AU7165891A (en) Tumor-specific, cell surface-binding monoclonal antibodies
AU1693995A (en) Phosphacan, nucleic acids encoding thereof and antibodies thereto
AU4889393A (en) Human monoclonal anti-peptide antibody and DNA encoding thereof
AU7504691A (en) Monoclonal antibodies against pp4, processes for the preapration thereof and the use thereof
EP0609292A4 (en) Soluble variants of type i membrane proteins, and methods of using them.